Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuropharmacokinetics of Eribulin in Brain Tumors
NCT02338037Phase 1Completed
- Sponsor
- City of Hope
- Start
- Sep 2015
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eribulin in brain tumor, sponsored by City of Hope. Primary endpoints: Time of Maximum Concentration up to 1 week, Maximum Concentration up to 1 week and 3 more. Started Sep 2015; status: completed.
02
Drugs
eribulin
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT02338037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338037.